publication date: Jul. 20, 2018
Conversation with The Cancer Letter Julia Beaver: SPARTAN and PROSPER showed MFS improvements greater than 20 months
Director, Division of Oncology Products 1, FDA Center for Drug Evaluation and Research
The endpoint of metastasis-free survival is unlikely to be used in settings beyond non-metastatic castration-resistant prostate cancer, said Julia Beaver, director of Division of Oncology Products 1 at the FDA Center for Drug Evaluation and Research.
Beaver spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
A few days ago, FDA officials, you among them, wrote a perspective piece for NEJM about the new endpoint of metastasis-free survival. How is this endpoint different from other endpoints used by the agency? What does it see that other metrics of delay in progression don’t see?
Metastasis-free survival is a time to event endpoint that measures the time from randomization to distant radiographic disease or death. Similar to other more commonly used endpoints, such as disease-free survival or recurrence-free survival, metastasis-free survival includes the transition from non-metastatic … Continue reading Julia Beaver: SPARTAN and PROSPER showed MFS improvements greater than 20 months
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.